{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T04:38:23Z","timestamp":1782448703103,"version":"3.54.5"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T00:00:00Z","timestamp":1681257600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T00:00:00Z","timestamp":1681257600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s10549-023-06926-y","type":"journal-article","created":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T00:03:02Z","timestamp":1681257782000},"page":"445-456","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Management of the axilla in postmenopausal patients with cN0 hormone receptor-positive\/HER2-negative breast cancer treated with neoadjuvant endocrine therapy and its prognostic impact"],"prefix":"10.1007","volume":"199","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3398-0570","authenticated-orcid":false,"given":"Amparo","family":"Garcia-Tejedor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catalina","family":"Falo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergi","family":"Fernandez-Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Laplana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Gil-Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Soler-Monso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyn","family":"Martinez-Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Calpelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Teresa","family":"Bajen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Benitez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul","family":"Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Petit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Guma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agostina","family":"Stradella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Lopez-Ojeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Ponce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria J.","family":"Pla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1485-5080","authenticated-orcid":false,"given":"Sonia","family":"Pernas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,12]]},"reference":[{"issue":"26","key":"6926_CR1","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1056\/NEJMra1307118","volume":"383","author":"HJ Burstein","year":"2020","unstructured":"Burstein HJ (2020) Systemic therapy for estrogen receptor-positive, her2-negative breast cancer. N Engl J Med 383(26):2557\u20132570","journal-title":"N Engl J Med"},{"key":"6926_CR2","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/jama.2018.19323","volume":"321","author":"AG Waks","year":"2019","unstructured":"Waks AG, Winer EP (2019) Breast cancer treatment: a review. JAMA: J Am Med Assoc Am Med Assoc 321:288\u2013300","journal-title":"JAMA: J Am Med Assoc Am Med Assoc"},{"issue":"24","key":"6926_CR3","doi-asserted-by":"publisher","first-page":"8715","DOI":"10.1158\/1078-0432.CCR-05-0539","volume":"11","author":"L Gianni","year":"2005","unstructured":"Gianni L, Baselga J, Eiermann W, Porta VG, Semiglazov V, Lluch A et al (2005) Feasibility and tolerability of sequential doxorubicin\/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clin Cancer Res 11(24):8715\u20138721","journal-title":"Clin Cancer Res"},{"issue":"16","key":"6926_CR4","doi-asserted-by":"publisher","first-page":"5678","DOI":"10.1158\/1078-0432.CCR-04-2421","volume":"11","author":"R Rouzier","year":"2005","unstructured":"Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K et al (2005) Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11(16):5678\u20135685","journal-title":"Clin Cancer Res"},{"issue":"11","key":"6926_CR5","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1001\/jamaoncol.2021.2132","volume":"7","author":"T Sella","year":"2021","unstructured":"Sella T, Weiss A, Mittendorf EA, King TA, Pilewskie M, Giuliano AE et al (2021) Neoadjuvant endocrine therapy in clinical practice: a review. JAMA Oncol 7(11):1700\u20131708","journal-title":"JAMA Oncol"},{"issue":"9","key":"6926_CR6","doi-asserted-by":"publisher","first-page":"3393","DOI":"10.1245\/s10434-020-08530-6","volume":"27","author":"A Weiss","year":"2020","unstructured":"Weiss A, King TA, Mittendorf EA (2020) The landmark series: neoadjuvant endocrine therapy for breast cancer. Ann Surg Oncol 27(9):3393\u20133401","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"6926_CR7","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S1470-2045(13)70166-9","volume":"14","author":"T Kuehn","year":"2013","unstructured":"Kuehn T, Bauerfeind I, Fehm T, Fleige B, Hausschild M, Helms G et al (2013) Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol 14(7):609\u2013618","journal-title":"Lancet Oncol"},{"issue":"9","key":"6926_CR8","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid P, Cortes J, Pusztai L, McArthur H, K\u00fcmmel S, Bergh J et al (2020) Pembrolizumab for early triple-negative breast cancer. N Engl J Med 382(9):810\u2013821","journal-title":"N Engl J Med"},{"issue":"5","key":"6926_CR9","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1111\/tbj.13763","volume":"26","author":"S Fernandez-Gonzalez","year":"2020","unstructured":"Fernandez-Gonzalez S, Falo C, Pla MJ, Verdaguer P, Nu\u00f1ez D, Guma A et al (2020) Predictive factors for omitting lymphadenectomy in patients with node-positive breast cancer treated with neo-adjuvant systemic therapy. Breast J 26(5):888\u2013896","journal-title":"Breast J"},{"issue":"12","key":"6926_CR10","doi-asserted-by":"publisher","first-page":"4669","DOI":"10.1245\/s10434-020-08905-9","volume":"27","author":"A Stafford","year":"2020","unstructured":"Stafford A, Williams A, Edmiston K, Cocilovo C, Cohen R, Bruce S et al (2020) Axillary response in patients undergoing neoadjuvant endocrine treatment for node-positive breast cancer: systematic literature review and NCDB analysis. Ann Surg Oncol 27(12):4669\u20134677","journal-title":"Ann Surg Oncol"},{"key":"6926_CR11","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.clbc.2017.08.014","volume":"18","author":"S Fernandez-Gonzalez","year":"2018","unstructured":"Fernandez-Gonzalez S, Falo C, Pla MJ, Pernas S, Bajen M, Soler T et al (2018) The shift from sentinel lymph node biopsy performed either before or after neoadjuvant systemic therapy in the clinical negative nodes of breast cancer patients. Results and the advantages and disadvantages of both procedures. Clin Breast Cancer 18:71\u20137","journal-title":"Clin Breast Cancer"},{"issue":"3","key":"6926_CR12","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1200\/JCO.2005.01.5784","volume":"24","author":"CM Rudenstam","year":"2006","unstructured":"Rudenstam CM, Zahrieh D, Forbes JF, Crivellari D, Holmberg SB, Rey P et al (2006) Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group trial 10\u201393. J Clin Oncol 24(3):337\u2013344","journal-title":"J Clin Oncol"},{"issue":"13","key":"6926_CR13","doi-asserted-by":"publisher","first-page":"4326","DOI":"10.1245\/s10434-019-07785-y","volume":"26","author":"A Weiss","year":"2019","unstructured":"Weiss A, Wong S, Golshan M, Freedman RA, Metzger O, Bellon J et al (2019) Patterns of axillary management in stages 2 and 3 hormone receptor-positive breast cancer by initial treatment approach. Ann Surg Oncol 26(13):4326\u20134336","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"6926_CR14","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1080\/14737140.2023.2162043","volume":"23","author":"C Mart\u00ednez-P\u00e9rez","year":"2023","unstructured":"Mart\u00ednez-P\u00e9rez C, Turnbull AK, Kay C, Dixon JM (2023) Neoadjuvant endocrine therapy in postmenopausal women with HR+\/HER2\u2212 breast cancer. Expert Rev Anticancer Ther 23(1):67\u201386","journal-title":"Expert Rev Anticancer Ther"},{"issue":"10","key":"6926_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms21103528","volume":"21","author":"G Barchiesi","year":"2020","unstructured":"Barchiesi G, Mazzotta M, Krasniqi E, Pizzuti L, Marinelli D, Capomolla E et al (2020) Neoadjuvant endocrine therapy in breast cancer: current knowledge and future perspectives. Int J Mol Sci 21(10):1\u201323","journal-title":"Int J Mol Sci"},{"issue":"6","key":"6926_CR16","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/sj.bjc.6605845","volume":"103","author":"YH Chia","year":"2010","unstructured":"Chia YH, Ellis MJ, Ma CX (2010) Neoadjuvant endocrine therapy in primary breast cancer: indications and use as a research tool. Br J Cancer 103(6):759\u2013764","journal-title":"Br J Cancer"},{"issue":"9","key":"6926_CR17","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1093\/annonc\/mdt303","volume":"24","author":"A Goldhirsch","year":"2013","unstructured":"Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Th\u00fcrlimann B et al (2013) Personalizing the treatment of women with early breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2013. Ann Oncol 24(9):2206\u201323","journal-title":"Ann Oncol"},{"issue":"5","key":"6926_CR18","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1148\/rg.335125214","volume":"33","author":"T Tirkes","year":"2013","unstructured":"Tirkes T, Hollar MA, Tann M, Kohli MD, Akisik F, Sandrasegaran K (2013) Response criteria in oncologic imaging: review of traditional and new criteria. Radiographics 33(5):1323\u20131341","journal-title":"Radiographics"},{"issue":"13","key":"6926_CR19","doi-asserted-by":"publisher","first-page":"8729","DOI":"10.1245\/s10434-021-10385-4","volume":"28","author":"BM Murphy","year":"2021","unstructured":"Murphy BM, Hoskin TL, Degnim AC, Boughey JC, Hieken TJ (2021) Surgical management of axilla following neoadjuvant endocrine therapy. Ann Surg Oncol 28(13):8729\u20138739","journal-title":"Ann Surg Oncol"},{"key":"6926_CR20","doi-asserted-by":"publisher","first-page":"4092","DOI":"10.1245\/s10434-022-11473-9","volume":"29","author":"O Friedman-Eldar","year":"2022","unstructured":"Friedman-Eldar O, Ozmen T, El Haddi SJ, Goel N, Tjendra Y, Kesmodel SB et al (2022) Axillary response to neoadjuvant therapy in node-positive estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients: predictors and oncologic outcomes. Ann Surg Oncol 29:4092","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"6926_CR21","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1245\/s10434-020-09073-6","volume":"28","author":"O Kantor","year":"2021","unstructured":"Kantor O, Wakeman M, Weiss A, Wong S, Laws A, Grossmith S et al (2021) Axillary management after neoadjuvant endocrine therapy for hormone receptor-positive breast cancer. Ann Surg Oncol 28(3):1358\u20131367","journal-title":"Ann Surg Oncol"},{"key":"6926_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-020-00177-6","author":"O Kantor","year":"2020","unstructured":"Kantor O, Wong S, Weiss A, Metzger O, Mittendorf EA, King TA et al (2020) Prognostic significance of residual nodal disease after neoadjuvant endocrine therapy for hormone receptor-positive breast cancer. npj Breast Cancer. https:\/\/doi.org\/10.1038\/s41523-020-00177-6","journal-title":"npj Breast Cancer"},{"issue":"8","key":"6926_CR23","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMoa020128","volume":"347","author":"B Fisher","year":"2002","unstructured":"Fisher B, Jeong J, Anderson S (2002) Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. New Engl J Med Engl J 347(8):567\u201375","journal-title":"New Engl J Med Engl J"},{"issue":"6","key":"6926_CR24","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1001\/jama.2011.90","volume":"305","author":"AE Giuliano","year":"2011","unstructured":"Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW et al (2011) Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA: J Am Med Assoc 305(6):569\u2013575","journal-title":"JAMA: J Am Med Assoc"},{"issue":"10","key":"6926_CR25","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1001\/jama.2017.11470","volume":"318","author":"AE Giuliano","year":"2017","unstructured":"Giuliano AE, Ballman KV, McCall L, Beitsch PD, Brennan MB, Kelemen PR et al (2017) Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA: J Am Med Assoc 318(10):918\u2013926","journal-title":"JAMA: J Am Med Assoc"},{"issue":"12","key":"6926_CR26","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/S1470-2045(14)70460-7","volume":"15","author":"M Donker","year":"2014","unstructured":"Donker M, van Tienhoven G, Straver ME, Meijnen P, van de Velde CJH, Mansel RE et al (2014) Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981\u201322023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol 15(12):1303\u20131310","journal-title":"Lancet Oncol"},{"key":"6926_CR27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01565","author":"SAL Bartels","year":"2022","unstructured":"Bartels SAL, Donker M, Poncet C, Sauv N, Straver ME, Mansel RE et al (2022) Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer: 10-year results of the randomized controlled EORTC 10981\u201322023 AMAROS trial. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.22.01565","journal-title":"J Clin Oncol"},{"key":"6926_CR28","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1200\/JCO.21.02759","volume":"40","author":"UA Nitz","year":"2022","unstructured":"Nitz UA, Gluz O, K\u00fcmmel S, Christgen M, Braun M, Aktas B et al (2022) Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+\/HER2\u2013 Early Breast Cancer. J Clin Oncol. 40:2557\u20132567","journal-title":"J Clin Oncol."},{"issue":"11","key":"6926_CR29","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1016\/S1470-2045(20)30458-7","volume":"21","author":"I Smith","year":"2020","unstructured":"Smith I, Robertson J, Kilburn L, Wilcox M, Evans A, Holcombe C et al (2020) Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial. Lancet Oncol 21(11):1443\u20131454","journal-title":"Lancet Oncol"},{"key":"6926_CR30","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.breast.2021.04.010","volume":"58","author":"MG Davey","year":"2021","unstructured":"Davey MG, Ryan J, Boland MR, Barry MK, Lowery AJ, Kerin MJ (2021) Clinical utility of the 21-gene assay in predicting response to neoadjuvant endocrine therapy in breast cancer: A systematic review and meta-analysis. Breast 58:113\u2013120","journal-title":"Breast"},{"issue":"6","key":"6926_CR31","doi-asserted-by":"publisher","first-page":"R365","DOI":"10.1530\/ERC-18-0117","volume":"25","author":"IS Fentiman","year":"2018","unstructured":"Fentiman IS (2018) The endocrinology of male breast cancer. Endocr Relat Cancer 25(6):R365\u2013R373","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"6926_CR32","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1245\/s10434-020-09435-0","volume":"28","author":"O Kantor","year":"2021","unstructured":"Kantor O, King TA (2021) ASO Author Reflections: Tailoring Axillary Surgery After Neoadjuvant Endocrine Therapy for Breast Cancer. Ann Surg Oncol 28(3):1368\u20131369","journal-title":"Ann Surg Oncol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-023-06926-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-023-06926-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-023-06926-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T13:54:16Z","timestamp":1683813256000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-023-06926-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,12]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["6926"],"URL":"https:\/\/doi.org\/10.1007\/s10549-023-06926-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2394671\/v1","asserted-by":"object"}]},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,12]]},"assertion":[{"value":"20 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"S.P. has served as an advisor\/consultant for AstraZeneca, Daiichi Sankyo Eisai, Novartis, Polyphor, Roche, Pierre-Fabre, Pfizer, and SeattleGenetics. All other authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted according to the guidelines of the Declaration of Helsinki and was approved by the Institutional Review Board of Hospital Universitari de Bellvitge (protocol code 247\/06, approved in November 2006).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all study participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}